Literature DB >> 3359697

Long-term follow-up of patients with steroid-dependent, minimal change nephrotic syndrome.

C Kashtan1, T Melvin, Y Kim.   

Abstract

A subgroup of patients with steroid-responsive minimal change nephrotic syndrome (MCNS) is classified as steroid-dependent because of repeated relapses of proteinuria during prednisone taper, or within four weeks of withdrawal of prednisone. The long-term outcome of this subgroup of patients has not been documented. Thirteen patients with onset of steroid-dependent MCNS (biopsy-proven) in childhood have been followed for 10-22 years (mean 15.6 years); 8 patients have been in stable remission for 2-13 years (mean 5.5 years); 3 remain steroid-dependent 12, 18 and 22 years after onset; and 2 had steroid-responsive relapses after 5 and 8 years of remission. In 3 patients steroid-dependent MCNS remitted without cytotoxic therapy 7-11 years after onset. Cyclophosphamide was administered to the remaining 10 patients: 8 had prolonged remissions (1.1-13 years, mean 4.3 years) and 2 relapsed shortly after cyclophosphamide therapy. Of the 8 patients who had prolonged remissions after cyclophosphamide, 3 have had no relapses 5-13 years after therapy. In 5 of these 8 patients steroid-dependency recurred 1.1-3 years after cyclophosphamide and a second course was given, resulting in remissions of 1.4-8 years in 3 patients, change to a frequently relapsing pattern in 1 patient and remission of 3 months in one patient who then became steroid-dependent again. We conclude that the long-term outcome of steroid-dependent MCNS is favorable. Cyclophosphamide is useful in the management of these patients and a prolonged course of alternate-day prednisone therapy after cyclophosphamide may be helpful in maintaining remission.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3359697

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  5 in total

1.  Long-term results of two unconventional agents in steroid-dependent nephrotic children.

Authors:  Ahmed Farouk Donia; Hesham Mohamed Ammar; Amgad El-Baz El-Agroudy; Fatma El-Husseini Moustafa; Mohamed Abdel-Kader Sobh
Journal:  Pediatr Nephrol       Date:  2005-07-27       Impact factor: 3.714

2.  Growth in boys with idiopathic nephrotic syndrome on long-term cyclosporin and steroid treatment.

Authors:  Valérie Leroy; Véronique Baudouin; Corinne Alberti; Geneviève Guest; Patrick Niaudet; Chantal Loirat; Georges Deschenes; Paul Czernichow; Dominique Simon
Journal:  Pediatr Nephrol       Date:  2009-08-11       Impact factor: 3.714

Review 3.  Management of nephrotic syndrome in childhood.

Authors:  T Melvin; W Bennett
Journal:  Drugs       Date:  1991-07       Impact factor: 9.546

4.  Pulse cyclophosphamide therapy in steroid-dependent nephrotic syndrome.

Authors:  Narayan Prasad; Sanjeev Gulati; Raj Kumar Sharma; Uttam Singh; Muffazal Ahmed
Journal:  Pediatr Nephrol       Date:  2004-03-09       Impact factor: 3.714

5.  Impact of rituximab on height and weight in children with refractory steroid-dependent nephrotic syndrome.

Authors:  Mai Sato; Shuichi Ito; Masao Ogura; Koichi Kamei
Journal:  Pediatr Nephrol       Date:  2014-03-07       Impact factor: 3.714

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.